- •Contents
- •Contributors
- •Part I General Principles of Cell Death
- •1 Human Caspases – Apoptosis and Inflammation Signaling Proteases
- •1.1. Apoptosis and limited proteolysis
- •1.2. Caspase evolution
- •2. ACTIVATION MECHANISMS
- •2.2. The activation platforms
- •2.4. Proteolytic maturation
- •3. CASPASE SUBSTRATES
- •4. REGULATION BY NATURAL INHIBITORS
- •REFERENCES
- •2 Inhibitor of Apoptosis Proteins
- •2. CELLULAR FUNCTIONS AND PHENOTYPES OF IAP
- •3. IN VIVO FUNCTIONS OF IAP FAMILY PROTEINS
- •4. SUBCELLULAR LOCATIONS OF IAP
- •8. IAP–IAP INTERACTIONS
- •10. ENDOGENOUS ANTAGONISTS OF IAP
- •11. IAPs AND DISEASE
- •SUGGESTED READINGS
- •1. INTRODUCTION
- •2.1. The CD95 (Fas/APO-1) system
- •2.1.1. CD95 and CD95L: discovery of the first direct apoptosis-inducing receptor-ligand system
- •2.1.2. Biochemistry of CD95 apoptosis signaling
- •2.2. The TRAIL (Apo2L) system
- •3.1. The TNF system
- •3.1.1. Biochemistry of TNF signal transduction
- •3.1.2. TNF and TNF blockers in the clinic
- •3.2. The DR3 system
- •4. THE DR6 SYSTEM
- •6. CONCLUDING REMARKS AND OUTLOOK
- •SUGGESTED READINGS
- •4 Mitochondria and Cell Death
- •1. INTRODUCTION
- •2. MITOCHONDRIAL PHYSIOLOGY
- •3. THE MITOCHONDRIAL PATHWAY OF APOPTOSIS
- •9. CONCLUSIONS
- •SUGGESTED READINGS
- •1. INTRODUCTION
- •3. INHIBITING APOPTOSIS
- •4. INHIBITING THE INHIBITORS
- •6. THE BCL-2 FAMILY AND CANCER
- •SUGGESTED READINGS
- •6 Endoplasmic Reticulum Stress Response in Cell Death and Cell Survival
- •1. INTRODUCTION
- •2. THE ESR IN YEAST
- •3. THE ESR IN MAMMALS
- •4. THE ESR AND CELL DEATH
- •5. THE ESR IN DEVELOPMENT AND TISSUE HOMEOSTASIS
- •6. THE ESR IN HUMAN DISEASE
- •7. CONCLUSION
- •7 Autophagy – The Liaison between the Lysosomal System and Cell Death
- •1. INTRODUCTION
- •2. AUTOPHAGY
- •2.2. Physiologic functions of autophagy
- •2.3. Autophagy and human pathology
- •3. AUTOPHAGY AND CELL DEATH
- •3.1. Autophagy as anti–cell death mechanism
- •3.2. Autophagy as a cell death mechanism
- •3.3. Molecular players of the autophagy–cell death cross-talk
- •4. AUTOPHAGY, CELLULAR DEATH, AND CANCER
- •5. CONCLUDING REMARKS AND PENDING QUESTIONS
- •SUGGESTED READINGS
- •8 Cell Death in Response to Genotoxic Stress and DNA Damage
- •1. TYPES OF DNA DAMAGE AND REPAIR SYSTEMS
- •2. DNA DAMAGE RESPONSE
- •2.2. Transducers
- •2.3. Effectors
- •4. CHROMATIN MODIFICATIONS
- •5. CELL CYCLE CHECKPOINT REGULATION
- •6. WHEN REPAIR FAILS: SENESCENCE VERSUS APOPTOSIS
- •6.1. DNA damage response and the induction of apoptosis
- •6.2. p53-independent mechanisms of apoptosis
- •6.3. DNA damage response and senescence induction
- •7. DNA DAMAGE FROM OXIDATIVE STRESS
- •SUGGESTED READINGS
- •9 Ceramide and Lipid Mediators in Apoptosis
- •1. INTRODUCTION
- •3.1. Basic cell signaling often involves small molecules
- •3.2. Sphingolipids are cell-signaling molecules
- •3.2.1. Ceramide induces apoptosis
- •3.2.2. Ceramide accumulates during programmed cell death
- •3.2.3. Inhibition of ceramide production alters cell death signaling
- •4.1. Ceramide is generated through SM hydrolysis
- •4.3. aSMase can be activated independently of extracellular receptors to regulate apoptosis
- •4.4. Controversial aspects of the role of aSMase in apoptosis
- •4.5. De novo ceramide synthesis regulates programmed cell death
- •4.6. p53 and Bcl-2–like proteins are connected to de novo ceramide synthesis
- •4.7. The role and regulation of de novo synthesis in ceramide-mediated cell death is poorly understood
- •5. CONCLUDING REMARKS AND FUTURE DIRECTIONS
- •5.1. Who? (Which enzyme?)
- •5.2. What? (Which ceramide?)
- •5.3. Where? (Which compartment?)
- •5.4. When? (At what steps?)
- •5.5. How? (Through what mechanisms?)
- •5.6. What purpose?
- •6. SUMMARY
- •SUGGESTED READINGS
- •1. General Introduction
- •1.1. Cytotoxic lymphocytes and apoptosis
- •2. CYTOTOXIC GRANULES AND GRANULE EXOCYTOSIS
- •2.1. Synthesis and loading of the cytotoxic granule proteins into the secretory granules
- •2.2. The immunological synapse
- •2.3. Secretion of granule proteins
- •2.4. Uptake of proapoptotic proteins into the target cell
- •2.5. Activation of death pathways by granzymes
- •3. GRANULE-BOUND CYTOTOXIC PROTEINS
- •3.1. Perforin
- •3.2. Granulysin
- •3.3. Granzymes
- •3.3.1. GrB-mediated apoptosis
- •3.3.2. GrA-mediated cell death
- •3.3.3. Orphan granzyme-mediated cell death
- •5. CONCLUSIONS
- •REFERENCES
- •Part II Cell Death in Tissues and Organs
- •1.1. Death by trophic factor deprivation
- •1.2. Key molecules regulating neuronal apoptosis during development
- •1.2.1. Roles of caspases and Apaf-1 in neuronal cell death
- •1.2.2. Role of Bcl-2 family members in neuronal cell death
- •1.3. Signal transduction from neurotrophins and neurotrophin receptors
- •1.3.1. Signals for survival
- •1.3.2. Signals for death
- •2.1. Apoptosis in neurodegenerative diseases
- •2.1.4. Amyotrophic lateral sclerosis
- •2.2. Necrotic cell death in neurodegenerative diseases
- •2.2.1. Calpains
- •2.2.2. Cathepsins
- •3. CONCLUSIONS
- •ACKNOWLEDGMENT
- •SUGGESTED READINGS
- •ACKNOWLEDGMENT
- •SUGGESTED READINGS
- •1. INTRODUCTION
- •5. S-NITROSYLATION OF PARKIN
- •7. POTENTIAL TREATMENT OF EXCESSIVE NMDA-INDUCED Ca2+ INFLUX AND FREE RADICAL GENERATION
- •8. FUTURE THERAPEUTICS: NITROMEMANTINES
- •9. CONCLUSIONS
- •Acknowledgments
- •SUGGESTED READINGS
- •3. MITOCHONDRIAL PERMEABILITY TRANSITION ACTIVATED BY Ca2+ AND OXIDATIVE STRESS
- •4.1. Mitochondrial apoptotic pathways
- •4.2. Bcl-2 family proteins
- •4.3. Caspase-dependent apoptosis
- •4.4. Caspase-independent apoptosis
- •4.5. Calpains in ischemic neural cell death
- •5. SUMMARY
- •ACKNOWLEDGMENTS
- •SUGGESTED READINGS
- •1. INTRODUCTION
- •2. HISTORICAL ANTECEDENTS
- •7.1. Activation of p21 waf1/cip1: Targeting extrinsic and intrinsic pathways to death
- •8. CONCLUSION
- •ACKNOWLEDGMENTS
- •REFERENCES
- •16 Apoptosis and Homeostasis in the Eye
- •1.1. Lens
- •1.2. Retina
- •2. ROLE OF APOPTOSIS IN DISEASES OF THE EYE
- •2.1. Glaucoma
- •2.2. Age-related macular degeneration
- •4. APOPTOSIS AND OCULAR IMMUNE PRIVILEGE
- •5. CONCLUSIONS
- •SUGGESTED READINGS
- •17 Cell Death in the Inner Ear
- •3. THE COCHLEA IS THE HEARING ORGAN
- •3.1. Ototoxic hair cell death
- •3.2. Aminoglycoside-induced hair cell death
- •3.3. Cisplatin-induced hair cell death
- •3.4. Therapeutic strategies to prevent hair cell death
- •3.5. Challenges to studies of hair cell death
- •4. SPIRAL GANGLION NEURON DEATH
- •4.1. Neurotrophic support from sensory hair cells and supporting cells
- •4.2. Afferent activity from hair cells
- •4.3. Molecular manifestations of spiral ganglion neuron death
- •4.4. Therapeutic interventions to prevent SGN death
- •ACKNOWLEDGMENTS
- •SUGGESTED READINGS
- •18 Cell Death in the Olfactory System
- •1. Introduction
- •2. Anatomical Aspects
- •3. Life and Death in the Olfactory System
- •3.1. Olfactory epithelium
- •3.2. Olfactory bulb
- •REFERENCES
- •1. Introduction
- •3.1. Beta cell death in the development of T1D
- •3.2. Mechanisms of beta cell death in type 1 diabetes
- •3.2.1. Apoptosis signaling pathways downstream of death receptors and inflammatory cytokines
- •3.2.2. Oxidative stress
- •3.3. Mechanisms of beta cell death in type 2 diabetes
- •3.3.1. Glucolipitoxicity
- •3.3.2. Endoplasmic reticulum stress
- •5. SUMMARY
- •Acknowledgments
- •REFERENCES
- •20 Apoptosis in the Physiology and Diseases of the Respiratory Tract
- •1. APOPTOSIS IN LUNG DEVELOPMENT
- •2. APOPTOSIS IN LUNG PATHOPHYSIOLOGY
- •2.1. Apoptosis in pulmonary inflammation
- •2.2. Apoptosis in acute lung injury
- •2.3. Apoptosis in chronic obstructive pulmonary disease
- •2.4. Apoptosis in interstitial lung diseases
- •2.5. Apoptosis in pulmonary arterial hypertension
- •2.6. Apoptosis in lung cancer
- •SUGGESTED READINGS
- •21 Regulation of Cell Death in the Gastrointestinal Tract
- •1. INTRODUCTION
- •2. ESOPHAGUS
- •3. STOMACH
- •4. SMALL AND LARGE INTESTINE
- •5. LIVER
- •6. PANCREAS
- •7. SUMMARY AND CONCLUDING REMARKS
- •SUGGESTED READINGS
- •22 Apoptosis in the Kidney
- •1. NORMAL KIDNEY STRUCTURE AND FUNCTION
- •3. APOPTOSIS IN ADULT KIDNEY DISEASE
- •4. REGULATION OF APOPTOSIS IN KIDNEY CELLS
- •4.1. Survival factors
- •4.2. Lethal factors
- •4.2.1. TNF superfamily cytokines
- •4.2.2. Other cytokines
- •4.2.3. Glucose
- •4.2.4. Drugs and xenobiotics
- •4.2.5. Ischemia-reperfusion and sepsis
- •5. THERAPEUTIC APPROACHES
- •SUGGESTED READINGS
- •1. INTRODUCTION
- •2. APOPTOSIS IN THE NORMAL BREAST
- •2.1. Occurrence and role of apoptosis in the developing breast
- •2.2.2. Death ligands and death receptor pathway
- •2.2.4. LIF-STAT3 proapoptotic signaling
- •2.2.5. IGF survival signaling
- •2.2.6. Regulation by adhesion
- •2.2.7. PI3K/AKT pathway: molecular hub for survival signals
- •2.2.8. Downstream regulators of apoptosis: the BCL-2 family members
- •3. APOPTOSIS IN BREAST CANCER
- •3.1. Apoptosis in breast tumorigenesis and cancer progression
- •3.2. Molecular dysregulation of apoptosis in breast cancer
- •3.2.1. Altered expression of death ligands and their receptors in breast cancer
- •3.2.2. Deregulation of prosurvival growth factors and their receptors
- •3.2.3. Alterations in cell adhesion and resistance to anoikis
- •3.2.4. Enhanced activation of the PI3K/AKT pathway in breast cancer
- •3.2.5. p53 inactivation in breast cancer
- •3.2.6. Altered expression of BCL-2 family of proteins in breast cancer
- •5. CONCLUSION
- •SUGGESTED READINGS
- •1. INTRODUCTION
- •2. DETECTING CELL DEATH IN THE FEMALE GONADS
- •4. APOPTOSIS AND FEMALE REPRODUCTIVE AGING
- •6. CONCLUDING REMARKS
- •REFERENCES
- •25 Apoptotic Signaling in Male Germ Cells
- •1. INTRODUCTION
- •3.1. Murine models
- •3.2. Primate models
- •3.3. Pathways of caspase activation and apoptosis
- •3.4. Apoptotic signaling in male germ cells
- •5. P38 MITOGEN-ACTIVATED PROTEIN KINASE (MAPK) AND NITRIC OXIDE (NO)–MEDIATED INTRINSIC PATHWAY SIGNALING CONSTITUTES A CRITICAL COMPONENT OF APOPTOTIC SIGNALING IN MALE GERM CELLS AFTER HORMONE DEPRIVATION
- •11. CONCLUSIONS AND PERSPECTIVES
- •REFERENCES
- •26 Cell Death in the Cardiovascular System
- •1. INTRODUCTION
- •2. CELL DEATH IN THE VASCULATURE
- •2.1. Apoptosis in the developing blood vessels
- •2.2. Apoptosis in atherosclerosis
- •2.2.1. Vascular smooth muscle cells
- •2.2.2. Macrophages
- •2.2.3. Regulation of apoptosis in atherosclerosis
- •2.2.4. Necrosis and autophagy in atherosclerosis
- •3. CELL DEATH IN THE MYOCARDIUM
- •3.1. Cell death in myocardial infarction
- •3.1.1. Apoptosis in myocardial infarction
- •3.1.2. Necrosis in myocardial infarction
- •3.1.3. Autophagy in myocardial infarction
- •3.2. Cell death in heart failure
- •3.2.1. Apoptosis in heart failure
- •3.2.2. Necrosis in heart failure
- •3.2.3. Autophagy in heart failure
- •4. CONCLUDING REMARKS
- •ACKNOWLEDGMENTS
- •REFERENCES
- •27 Cell Death Regulation in Muscle
- •1. INTRODUCTION TO MUSCLE
- •1.1. Skeletal muscle adaptation to endurance training
- •1.2. Myonuclear domains
- •2. MITOCHONDRIALLY MEDIATED APOPTOSIS IN MUSCLE
- •2.1. Skeletal muscle apoptotic susceptibility
- •4. APOPTOSIS IN MUSCLE DURING AGING AND DISEASE
- •4.1. Aging
- •4.2. Type 2 diabetes mellitus
- •4.3. Cancer cachexia
- •4.4. Chronic heart failure
- •6. CONCLUSION
- •SUGGESTED READINGS
- •28 Cell Death in the Skin
- •1. INTRODUCTION
- •2. CELL DEATH IN SKIN HOMEOSTASIS
- •2.1. Cornification and apoptosis
- •2.2. Death receptors in the skin
- •3. CELL DEATH IN SKIN PATHOLOGY
- •3.1. Sunburn
- •3.2. Skin cancer
- •3.3. Necrolysis
- •3.4. Pemphigus
- •3.5. Eczema
- •3.6. Graft-versus-host disease
- •4. CONCLUDING REMARKS AND PERSPECTIVES
- •ACKNOWLEDGMENTS
- •SUGGESTED READINGS
- •29 Apoptosis and Cell Survival in the Immune System
- •2.1. Survival of early hematopoietic progenitors
- •2.2. Sizing of the T-cell population
- •2.2.1. Establishing central tolerance
- •2.2.2. Peripheral tolerance
- •2.2.3. Memory T cells
- •2.3. Control of apoptosis in B-cell development
- •2.3.1. Early B-cell development
- •2.3.2. Deletion of autoreactive B cells
- •2.3.3. Survival and death of activated B cells
- •3. IMPAIRED APOPTOSIS AND LEUKEMOGENESIS
- •4. CONCLUSIONS
- •ACKNOWLEDGMENTS
- •REFERENCES
- •30 Cell Death Regulation in the Hematopoietic System
- •1. INTRODUCTION
- •2. HEMATOPOIETIC STEM CELLS
- •4. ERYTHROPOIESIS
- •5. MEGAKARYOPOIESIS
- •6. GRANULOPOIESIS
- •7. MONOPOIESIS
- •8. CONCLUSION
- •ACKNOWLEDGMENTS
- •REFERENCES
- •31 Apoptotic Cell Death in Sepsis
- •1. INTRODUCTION
- •2. HOST INFLAMMATORY RESPONSE TO SEPSIS
- •3. CLINICAL OBSERVATIONS OF CELL DEATH IN SEPSIS
- •3.1. Sepsis-induced apoptosis
- •3.2. Necrotic cell death in sepsis
- •4.1. Central role of apoptosis in sepsis mortality: immune effector cells and gut epithelium
- •4.2. Apoptotic pathways in sepsis-induced immune cell death
- •4.3. Investigations implicating the extrinsic apoptotic pathway in sepsis
- •4.4. Investigations implicating the intrinsic apoptotic pathway in sepsis
- •5. THE EFFECT OF APOPTOSIS ON THE IMMUNE SYSTEM
- •5.1. Cellular effects of an increased apoptotic burdens
- •5.2. Network effects of selective loss of immune cell types
- •5.3. Studies of immunomodulation by apoptotic cells in other fields
- •7. CONCLUSION
- •REFERENCES
- •32 Host–Pathogen Interactions
- •1. INTRODUCTION
- •2. FROM THE PATHOGEN PERSPECTIVE
- •2.1. Commensals versus pathogens
- •2.2. Pathogen strategies to infect the host
- •3. HOST DEFENSE
- •3.1. Antimicrobial peptides
- •3.2. PRRs and inflammation
- •3.2.1. TLRs
- •3.2.2. NLRs
- •3.2.3. The Nod signalosome
- •3.2.4. The inflammasome
- •3.3. Cell death
- •3.3.1. Apoptosis and pathogen clearance
- •3.3.2. Pyroptosis
- •3.2.3. Caspase-independent cell death
- •3.2.4. Autophagy and autophagic cell death
- •4. CONCLUSIONS
- •REFERENCES
- •Part III Cell Death in Nonmammalian Organisms
- •1. PHENOTYPE AND ASSAYS OF YEAST APOPTOSIS
- •2.1. Pheromone-induced cell death
- •2.1.1. Colony growth
- •2.1.2. Killer-induced cell death
- •3. EXTERNAL STIMULI THAT INDUCE APOPTOSIS IN YEAST
- •4. THE GENETICS OF YEAST APOPTOSIS
- •5. PROGRAMMED AND ALTRUISTIC AGING
- •SUGGESTED READINGS
- •34 Caenorhabditis elegans and Apoptosis
- •1. Overview
- •2. KILLING
- •3. SPECIFICATION
- •4. EXECUTION
- •4.1. DNA degradation
- •4.2. Mitochondrial elimination
- •4.3. Engulfment
- •5. SUMMARY
- •SUGGESTED READINGS
- •35 Apoptotic Cell Death in Drosophila
- •2. DROSOPHILA CASPASES AND PROXIMAL REGULATORS
- •6. CLOSING COMMENTS
- •SUGGESTED READINGS
- •36 Analysis of Cell Death in Zebrafish
- •1. INTRODUCTION
- •2. WHY USE ZEBRAFISH TO STUDY CELL DEATH?
- •2.2. Molecular techniques to rapidly assess gene function in embryos
- •2.2.1. Studies of gene function using microinjections into early embryos
- •2.2.2. In situ hybridization and immunohistochemistry
- •2.3. Forward genetic screening
- •2.4. Drug and small-molecule screening
- •2.5. Transgenesis
- •2.6. Targeted knockouts
- •3.1. Intrinsic apoptosis
- •3.2. Extrinsic apoptosis
- •3.3. Chk-1 suppressed apoptosis
- •3.4. Anoikis
- •3.5. Autophagy
- •3.6. Necrosis
- •4. DEVELOPMENTAL CELL DEATH IN ZEBRAFISH EMBRYOS
- •5. THE P53 PATHWAY
- •6. PERSPECTIVES AND FUTURE DIRECTIONS
- •SUGGESTED READING
20 Apoptosis in the Physiology and Diseases of the Respiratory Tract
Christian Taube and Martin Schuler
The lung provides a huge contact interface between the organism and its environment. Its mucosal surfaces must permit gas exchange between the blood and air, but also act as a barrier against a plethora of microorganisms. In addition, inhaled toxins and particles may enter the organism via the lung. Accordingly, inflammatory airway and lung diseases are among the most prevalent human morbidities. Lung cancer, which in most cases can be attributed to tobacco smoking, is the leading cause of cancer-related mortality in the developed world. In this chapter, we summarize the role of apoptotic cell death in lung development and in clinical disease states.
1. APOPTOSIS IN LUNG DEVELOPMENT
The physiology and genetics of the branching program underlying lung development are just being unraveled. Following the initial separation of the lung bud from the prospective esophagus in the embryonic stage, apoptosis of mesenchymal and epithelial cells can be observed during the various stages of lung development. Regulation of developmental apoptosis has been linked to the expression of cytokines, such as transforming growth factor-β1 (TGF-β1) and insulin-like growth factor 1 (IGF-1), as well as additional apoptosis-related proteins and nitric oxide. In the early stages of lung development, apoptosis is mainly detectable in the mesenchymal tissue layer. Indeed, apoptosis was almost exclusively found in the regions of new bud formation or in the mesenchyme underlying branch points, thus providing space for the outgrowth of lung buds. During later stages of lung development, both alveolar epithelial and mesenchymal tissue apoptosis can be detected. At this time, apoptosis coincides with airway branching, decreased cell proliferation, and alveolar epithelial thin-
ning, thus implying cellular apoptosis as a significant contributor of lung remodeling. Alveolarization and microvascular maturation do not stop at birth, but continue up to a few years after birth(1). After birth, apoptosis emerges as an important process after extensive proliferation of type 2 alveolar epithelial cells, which are produced in higher numbers than actually required. Consequently, type 2 cells are removed either by differentiation or by apoptosis, thus preserving functional alveoli.
Using different approaches, genes encoding most of the core factors of the apoptotic machinery have been targeted in the mouse. Although some of these genetargeted mice exhibited developmental defects, none of them showed particular pathology in the respiratory tract or lung. This observation does not rule out an involvement of apoptosis regulators in lung physiology, as some of these knockout mice, such as those deficient in Mcl-1, cytochrome c, caspase-8, casper, or FADD, succumb during embryonic development, and their lung development cannot be examined. Recently, mice with targeted deletion of the miR-17 92 microRNA were described to exhibit embryonic lethality due to lung hypoplasia and cardiac defects. Examination of lung tissues revealed increased expression of the proapoptotic BH3-only protein Bim, and miR-17 92 was found to transcriptionally repress Bim. Overall, these findings suggest that apoptosis plays an important role in mammalian lung development.
2. APOPTOSIS IN LUNG PATHOPHYSIOLOGY
2.1. Apoptosis in pulmonary inflammation
The lung is characterized by a large mucosal surface at risk for exposure to many types of microorganisms (e.g., viral, bacterial) and irritants (e.g., ozone), which
221
222 |
CHRISTIAN TAUBE AND MARTIN SCHULER |
can lead sometimes to severe inflammatory reactions. Apoptotic cells are usually rapidly and effectively cleared from the lung so that no apoptotic cells are detectable in the healthy lung. Even during extensive inflammatory reactions, (e.g., during lung infection), few apoptotic cells are found in lung tissue. Neutrophils derived from broncho-alveolar lavage (BAL) samples of patients with pneumonia even display decreased rates of apoptosis. Also, during resolution of lung inflammation, apoptotic cells are rapidly removed by macrophages through cell recognition receptors (phosphatidylserine receptor, CD36, and alpha v integrins). Uptake of apoptotic cells by macrophages then leads to a noninflammatory environment by production of anti-inflammatory mediators that include TGF-β, interleukin-10 (IL-10), and prostaglandin E2 (PGE2). Indeed, in animal studies, instillation of apoptotic cells into the lung results in rapid resolution of inflammatory responses, suggesting that apoptosis and uptake of apoptotic cells provides an intrinsic anti-inflammatory circuit that attenuates proinflammatory responses. However, in several lung diseases, increased numbers of apoptotic cells have been described in the airways and lung tissue, implying either an increase in apoptosis or defects in clearance of apoptotic cells in pathophysiology. In cystic fibrosis, which is characterized by a massive influx of inflammatory cells and release of proteases in the lung, increased numbers of apoptotic neutrophils are detectable in the airway. This finding has been linked to cleavage of the phosphatidylserine receptor on macrophages by neutrophil elastase, which impairs the uptake of apoptotic cells and contributes to ongoing inflammation. Similarly, alveolar macrophages from patients with chronic obstructive pulmonary disease (COPD) are less effective in phagocytosing apoptotic airway epithelial cells as compared with controls. Also, increased apoptosis of lung structural cells has been described in several lung diseases, including acute lung injury, COPD, and lung fibrosis.
2.2. Apoptosis in acute lung injury
Acute lung injury (ALI) and the more severe acute respiratory distress syndrome (ARDS) represent clinical syndromes that result from complex responses of the lung to a multitude of direct and indirect stresses. Important pathophysiologic changes found in patients with ALI are alveolar inflammation and injury. Indeed, epithelial injury is one of the hallmarks of ALI in patients, and alveolar epithelial cells are especially affected. Similar to patients with pneumonia, only few apoptotic inflammatory cells are found in the lung, probably due to increases
in growth factors and rapid uptake of apoptotic granulocytes by macrophages. In contrast, it has recently become clear that increased apoptosis is detectable in parenchymal lung cells of adult patients with ALI and ARDS. Similar observations have also been reported in newborns with acute lung injury. Especially alveolar epithelia cells have been found to be apoptotic, leading to increased epithelial permeability and subsequent alveolar flooding. The increase in alveolar cell apoptosis could be mediated by increased levels of soluble Fas ligand (sFasL), which can be detected in BAL samples of patients with ALI and ARDS. During onset of ARDS, sFasL is highly biologically active and induces apoptosis of alveolar epithelial cells in vitro, particularly affecting distal epithelia cells. Also, in patients with ARDS, Fas expression on alveolar epithelial cells that line the alveolar walls is increased. Together, these findings are strongly suggestive that activation of the Fas pathway is an important contributor to alveolar epithelial cell apoptosis leading to the development of ALI and ARDS, in addition to other factors such as mechanical stress, hyperoxia, and hypoxia.
Animals models of ALI have confirmed that apoptosis of parenchymal lung cells contributes to acute lung damage. Indeed, direct instillation of sFasL into the lung or administration of an activating anti-Fas antibody leads to increased alveolar cell apoptosis associated with increased pulmonary inflammation. Also, meconium instillation into the lung, as a model for acute lung injury in newborns, leads to increased apoptosis of epithelial cells. Additionally, models of lung hyperoxia have revealed that apoptosis is a prominent component of the acute response, which is also mediated by Fas/FasL pathway. Other models of ALI involve instillation of bacterial lipopolysaccharides (LPS) into the lung. In these models, increased apoptosis of alveolar epithelial cells and interstitial inflammatory cells are also detectable. In addition to epithelial cell apoptosis, endothelial cell apoptosis can be found in models of hemorrhagic shock. Interestingly, administration of blocking anti-Fas antibodies or caspase-3 inhibitors attenuates lung injury after LPS instillation, suggesting that regulation of apoptosis could be a potential treatment of ARDS.
However, apoptosis also has beneficial effects during the resolution of inflammation after acute lung injury. Indeed, during resolution of ALI, hyperplasia of type II pneumocytes occurs as a reparative phenomenon. During clearance of inflammation, extensive apoptosis of type II pneumocytes mediated by Fas/FasL accounts for the disappearance of these cells from the lung. Therefore, although blocking apoptosis at an early stage of the disease might be beneficial for the course of ALI
APOPTOSIS IN THE PHYSIOLOGY AND DISEASES OF THE RESPIRATORY TRACT |
223 |
and ARDS, inhibiting apoptosis at later stages might be counter-indicated because apoptosis and engulfment of apoptotic cells are important events during resolution of inflammation.
2.3. Apoptosis in chronic obstructive pulmonary disease
COPD is a chronic respiratory disease characterized by airflow limitation that is not fully reversible. The airflow limitation usually is progressive and associated with inflammation of the lungs. COPD is a combination of two phenotypes, chronic obstructive bronchitis, defined clinically as chronic productive cough in combination with airflow obstruction, and emphysema, characterized pathologically as the presence of permanent enlargement of the airspaces distal to the terminal bronchioles, accompanied by destruction of their walls. COPD is the result of exposure to noxious particles. Cigarette smoke is the major risk factor for the development of this disease in the Western world. However, despite progress in the characterization of COPD, so far the pathophysiologic cause has not been identified. Several mechanisms have been suggested to contribute to the development of COPD. Airway inflammation, oxidative stress, a disrupted balance between proteolytic and antiproteolytic molecules in the lung, as well as premature aging and senescence are suspected to contribute to the development of COPD. In recent years, alternative mechanisms have been discussed. There is increasing evidence from studies in humans as well as data from animal models that defective homeostasis of apoptosis and proliferation in the lung might lead to a disruption of alveolar architecture, leading to emphysema.
Indeed, several studies in lung tissue samples from patients with COPD have described increased apoptosis as compared with controls. Increased apoptosis was found in several types of lung cells, including endothelial cells, interstitial cells, and alveolar epithelial cells. In addition, increased detection of active caspase-3 and expression of Bax and Bad as well as elevated levels of airway granzyme B and perforin have been reported, providing evidence for enhanced activation of proapoptotic pathways in these patients.
Animal models of COPD have also suggested an important role of apoptosis in the development of emphysema, even in the absence of significant inflammatory changes. Experimental observations, which describe alveolar enlargement as a result of alveolar and endothelial cell apoptosis, have supported the concept of a direct involvement of apoptosis in emphysema development. Direct targeting of alveolar cells in mice by intratracheal
administration of active caspase-3 or ceramide results in epithelial apoptosis and development of emphysematous changes in mice. Inhibition of growth factor signaling in the lung also results in increased apoptosis. Indeed, targeting vascular endothelial growth factor (VEGF) or VEGF receptor (VEGFR) in the lung increases apoptosis of alveolar cells, leading to enlargement of the alveolar space. This process can be attenuated by treatment with a caspase inhibitor, thus preventing apoptosis and development of emphysema. Similar to animal studies, decreased expression of VEGF and VEGFR has been detected in patients with emphysema, suggesting that epithelial and endothelial alveolar septal death due to a decrease of endothelial cell maintenance factors contributes to the pathogenesis of emphysema. Some studies have linked increased apoptosis with other pathophysiologic mechanisms of emphysema development (such as protease/antiprotease imbalance). Mice that over-express interferon γ in the lungs develop emphysema and have increased numbers of apoptotic parenchymal lung cells. Interestingly, inhibition of cathepsin S, an important elastase in the lung, results in decreased apoptosis and emphysema in interferon-expressing transgenic mice. This suggests that protease-dependent epithelial cell apoptosis is a critical event in the pathogenesis of alveolar remodeling and emphysema, linking apoptosis to protease/antiprotease imbalance. Overall, these findings show that apoptosis of lung cells plays an important role during the development of COPD and especially emphysema. Thus far, no therapeutic approaches have been clinically developed to prevent apoptosis in this patient group.
2.4. Apoptosis in interstitial lung diseases
Interstitial lung diseases constitute a heterogeneous collection of diseases that are characterized by a progressive distortion of the alveolar architecture and replacement by fibrotic tissue. The clinically most relevant form is idiopathic pulmonary fibrosis (IPF), which is characterized by progressive dyspnea, decline in lung function, and death within 3 to 4 years from diagnosis. Histopathologically, IPF typically shows a pattern of usual interstitial pneumonia, the cardinal features of which are patchy fibrosis with variable numbers of fi- broblastic foci interspersed with areas of normal or nearly normal lung. Although initial studies focused on the role of inflammation in inciting fibroblast activation and fibrosis, current concepts suggest a central role of the epithelium in IPF pathogenesis. It has been proposed that IPF is the result of ongoing alveolar epithelial
224 |
CHRISTIAN TAUBE AND MARTIN SCHULER |
injury and subsequent dysregulated repair associated with the formation of fibroblast-myofibroblast foci, which evolve into fibrosis. A relatively small increase in the rate of epithelial cell apoptosis is predicted to result in considerable cell loss over time and thus minor upregulation of epithelial apoptosis, especially of alveolar epithelial cells, could account for excessive epithelial loss. Therefore, it is likely that apoptosis of epithelial cells is important in the injury and repair processes present in IPF. Indeed, alveolar epithelial cell injury and apoptosis were found in the lungs of patients with IPF, even in areas that histologically seemed normal. Especially in areas where epithelial cells are in close proximity to myofibroblasts, increased epithelial cell apoptosis is frequently detectable. In addition, lung tissues from IPF patients exhibit increased expression of proapoptotic proteins (p53, Bax, and caspase-3) and decreased expression of antiapoptotic proteins (Bcl-2) in epithelial cells.
Animal studies have also demonstrated that apoptosis of alveolar epithelial cells is sufficient to induce pulmonary fibrosis. Intratracheal instillation of activating anti-Fas antibody induces apoptosis of alveolar epithelial cells and results in pulmonary fibrosis in rodents. Apoptosis is also induced by over-expression of TGF- β in the rodent lung, leading to inflammation, myofibroblast hyperplasia, tissue fibrosis, and honeycombing. Treatment with caspase inhibitors markedly ameliorates fibrosis and alveolar remodelling. In addition, apoptosis of alveolar epithelial cells is detected. In the commonly used bleomycin-induced pulmonary fibrosis model, direct inhibition of apoptosis by blocking the Fas/FasL pathway results in a blunted apoptotic response to bleomycin and decreased collagen production. Also, treatment with caspase inhibitors not only prevents apoptosis, but also reduces the histopathological grade of lung inflammation and decreases fibrosis.
2.5. Apoptosis in pulmonary arterial hypertension
Pulmonary hypertension (PH) is a hemodynamic and pathophysiological condition defined as an increase in pulmonary artery pressure ≥25 mmHg at rest as assessed by right heart catheterization. Pulmonary arterial hypertension (PAH) is a clinical condition characterized by the presence of pre-capillary PH in the absence of other causes of pre-capillary PH such as PH due to lung diseases, chronic thromboembolic PH, or other rare diseases. PAH includes different forms that share a similar clinical picture and virtually identical pathological changes like vasoconstriction, in situ thrombosis, and vascular remodeling of pulmonary arteries (Gaile et al. 2009).
PAH can be classified into five categories: (1) idiopathic PAH, (2) heritable PAH, (3) drugor toxin-induced PAH, (4) PAH associated with other diseases (e.g. connective tissue diseases, HIV infection, portal hypertension), and (5) persistent pulmonary hypertension of the newborn. PAH is a progressive disease characterized by abnormal muscularization of distal pulmonary arteries, striking reduction in arterial numbers, progressive intimal hyperplasia leading to occlusive changes in the pulmonary arteries, and so-called plexiform lesions. The initial pathological events are thought to be related to dysregulation of pulmonary artery smooth muscle proliferation. Increased proliferation and decreased apoptosis of pulmonary arterial smooth muscle could mediate thickening of the pulmonary vasculature, which subsequently would lead to reduced inner diameter and increased pulmonary vascular resistance. Several lines of evidence have suggested an impaired regulation of pulmonary artery smooth muscle proliferation. In a subset of PAH patients, loss-of-function mutations in bone morphogenetic protein receptor 2 (BMPR2) has been found. Activation of the BMPR2 pathway results normally in suppression of arterial smooth muscle cell proliferation. In contrast, arterial smooth muscle cells from patients with PAH were not inhibited in their proliferation after BMPR2 activation. Also, mediators that favor suppression of apoptosis (e.g., Bcl-2) are upregulated in lung vessels of patients with PAH. These findings suggest that some abnormalities described in PAH contribute to resistance to apoptosis and a proliferation/apoptosis imbalance within the vascular wall, thus leading to smooth muscle proliferation and vascular remodeling. These hypotheses are supported by the description of increased expression of the Survivin protein in remodeled pulmonary arteries from patients with PAH. In this regard, dysregulated Survivin expression is considered to be a major pathological mechanism in animal models of PAH, which have demonstrated Survivin over-expression coinciding with pulmonary vascular remodeling. Furthermore, inhibition of Survivin by gene therapy in these models resulted in pulmonary artery smooth muscle cell apoptosis and decreased pulmonary vascular resistance, heart failure, and vascular remodeling. Theses finding suggest that targeted pro-apoptotic agents could be a possible new therapeutic approach for patients with PAH.
2.6. Apoptosis in lung cancer
Lung cancer is the leading cause of cancer mortality in the United States and Western Europe. The main risk factor for the development of lung cancer is inhaled tobacco exposure. Smoking 20 cigarettes per day for
APOPTOSIS IN THE PHYSIOLOGY AND DISEASES OF THE RESPIRATORY TRACT |
225 |
20 years (i.e., 20 pack-years) increases the age-adjusted risk for lung cancer approximately 20-fold. In the light of the high prevalence of tobacco smoking in Asia, Eastern Europe, Latin America, and South America, lung cancer seems destined to become an even larger global health problem, with enormous socioeconomic and health care costs. Based on histology and clinical course, lung cancers have been grouped into small-cell lung cancer (SCLC), which comprises less than 20% of lung cancer cases, virtually all of which are associated with cigarette smoking, and non–small-cell lung cancers (NSCLC), which constitute more than 80% of lung cancer cases. The latter is a heterogeneous group composed of several histologies, such as squamous cell carcinoma (SCC), adenocarcinoma, large-cell carcinoma, bronchoalveolar carcinoma, and others. Historically, all NSCLCs have been uniformly treated. However, more recently it has been recognized that some NSCLC subgroups are more susceptible to certain therapies. For example, patients with adenocarcinoma and no smoking history have a high incidence of amplification and mutations of the epidermal growth factor receptor (EGFR), which make them prone to responding to EGFR tyrosine kinase inhibitors (TKIs), such as erlotinib or gefitinib. Also, the antifolate pemetrexed achieved superior survival outcomes in patients with adenocarcinoma and large-cell carcinoma, but not those with SCC. Further, SCC patients are excluded from receiving the anti-VEGF antibody bevacizumab in combination with chemotherapy because of a higher risk of bleeding complications. These clinical and histological distinctions are currently substantiated by more sophisticated efforts of tumor characterization, such as gene expression profiling and massively parallel sequencing. Hence it is expected that molecular predictors and specific targets will play an even larger role in future treatment decisions for patients with lung cancer.
Against this background, the analysis of apoptosis pathways in lung cancer is of particular importance. First, as in most cancers, deregulation of apoptosis is an important event in lung carcinogenesis. This is exemplified by inactivating mutations of the TP53 tumor suppressor gene, which are found in approximately half of lung cancers. Accordingly, loss of p53 accelerates tumor development in a mouse model of K-ras–induced lung carcinogenesis. p53 gene transfer and pharmacological restoration of p53 function have been shown to induce apoptosis in p53-defective lung cancer cells in vitro and in pilot studies of somatic gene therapy in vivo. Additional genes involved in apoptosis regulation were found to be differentially expressed in murine lung cancer models as well as in human lung cancer samples as compared with nonmalignant tissues. In addition,
hypothesis-driven studies have specifically addressed apoptosis regulators with known function. For example, in a transgenic model of Raf-induced lung carcinogenesis, the onset of tumor development was greatly delayed by targeted deletion of Bcl-2. Accordingly, protein expression patterns of various proand antiapoptotic Bcl-2 family proteins correlated with prognosis in surgically resected lung cancer patients in some studies, in addition to changes in caspase expression. Taken together, these studies support a role of apoptosis in the development and progression of lung cancer. Hence apoptosis-directed strategies merit examination for lung cancer prevention and treatment. Indeed, at present, a chemical inhibitor of antiapoptotic Bcl-2 family proteins (BH3 mimetic) is currently in clinical testing for SCLC. Prospective studies are needed to define a role for expression analysis of apoptosis regulators as prognostic factors or predictors for treatment decisions in lung cancer patients.
Second, cytotoxic chemotherapy and gamma radiation, which are both thought to exert at least some of their activities by inducing apoptosis, still provide the basis of current standard treatment protocols for patients with nonresectable advanced and metastatic lung cancers. In addition, EGFR mutations in lung cancer were shown to activate antiapoptotic pathways, and this was reversed by EGFR TKI treatment. Hence deregulation in apoptotic signal transduction could interfere with the therapeutic activity of lung cancer therapies. Alternatively, proapoptotic therapies could overcome resistance to current drugs in clinical use for NSCLC and SCLC patients. Expression of antiapoptotic Bcl-2 family proteins was found to interfere with drug sensitivity of cancer cells, which is overcome by gene transfer-mediated expression of proapoptotic Bcl-2 proteins. These studies provide a lead for the development of pharmacological compounds targeting anti-apoptotic Bcl-2 proteins in lung cancer. Of particular interest are so-called BH3 mimetics, which exhibit promising activity in preclinical models of SCLC and NSCLC. Additional apoptotic targets have been identified that could enhance the efficacy of cytotoxic lung cancer therapies. The mitochondrial protein Smac is thought to interfere with the inhibition of caspases by inhibitor of apoptosis (IAP) proteins. Accordingly, Smac-derived peptides were shown to sensitize lung cancer cells to cytotoxic anticancer drugs in vitro. However, recent studies with smallmolecule IAP inhibitors suggest a role in tumor necrosis factor (TNF) signaling, in addition to allowing caspase activation. Conditional expression of pp32/PHAPI, a putative modulator of apoptosome activity, sensitizes drug-resistant lung cancer cells to apoptosis in vitro and in vivo. Interestingly, high expression of pp32/PHAPI